Mallia Therapeutics and Northway Biotech Announce Partnership for the Manufacturing of Soluble CD83 Protein for Hair Loss Treatment
ERLANGEN, GERMANY AND VILNIUS, LITHUANIA, Feb 4, 2025 - (ACN Newswire via SeaPRwire.com) - Mallia Therapeutics ("Mallia"), a biopharmaceutical company developing novel treatments for hair loss, and Northway Biotech ("NBT"), a biologics Contract Development and Manufacturing Organization (CDMO), have announced a partnership for the development of the production process and manufacturing of Mallia's soluble CD83 protein (sCD83), a treatment aimed at promoting hair follicle formation and growth.Under the agreement, Northway Biotech will leverage its expertise in biologics manufacturing to develop the production process for the recombinant sCD83 protein for large-scale production, utilizing the Pichia pastoris expression system. This collaboration includes the development of analytical methods, technology scale-up, and the manufacturing of a cGMP Drug Substance.Dr. Manfred Groeppel, co-founder and Managing Director of Mallia Therapeutics, said: "With this partnership, we are advancing the development of sCD83 to turn our research into a scalable treatment for patients.""Interestingly, sCD83's mode of action induces both the formation of new hair follicles and thus hair growth, and has ...
